Quadruplex Master Switch Technology for Cancer Drugs

Reglagene is pioneering a novel approach to brain cancer treatment through its development of tubulin-targeting therapies that effectively penetrate the blood-brain barrier (BBB). Their lead therapy, RGN6024, is an orally administered microtubule targeting agent optimized for high-grade gliomas, including glioblastoma, as well as brain metastases from various cancers. This innovative treatment is designed to be well-tolerated and has demonstrated significant efficacy in preclinical studies, achieving over 84% tumor growth reduction compared to standard treatments. Unlike traditional therapies that are often hindered by efflux pumps in the brain, Reglagene's therapy remains active within the brain, continuously attacking tumors without being expelled.

In addition to its focus on brain cancers, Reglagene is also exploring the potential of its microtubule targeting agents for treating neurodegenerative diseases such as Parkinson's Disease. The company boasts an extensive portfolio of over 900 microtubule targeting agents, emphasizing their commitment to developing safe, effective, and accessible treatments. By leveraging the advantages of small-molecule medicines, Reglagene aims to provide therapies that can be administered orally, reducing the need for intravenous treatments that often come with significant side effects. This strategic focus on BBB penetration and patient-friendly administration positions Reglagene as a leader in transforming the landscape of brain disease therapies.

United States

Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies.

Reglagene

Company Details